Dr. Joel M. Brothers, MD

Dr. Brothers practices at Loma Linda University Medical Center in Loma Linda, California, part of Seventh-day Adventist Church.

Dr. Brothers' NPI, 1427311034, was assigned on June 19, 2012. Dr. Brothers graduated from Loma Linda University School Of Medicine in 2012. Dr. Brothers holds California license A141503.

Dr. Brothers' primary practice is Loma Linda University Medical Center, at 11234 Anderson St, Loma Linda, CA 92354 in San Bernardino County. The practice phone is (909) 558-4000.

Dr. Brothers' primary practice is Loma Linda University Medical Center in Loma Linda, California, part of Seventh-day Adventist Church. The medical group on file is Loma Linda University Faculty Medical Group (LLUFMG). Dmand AI also links Dr. Brothers to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Brothers practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Brothers' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Brothers is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Brothers' licenses on file in 2 states: California and Michigan.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, immune deficiency disease, lung cancer, lymphoma and multiple myeloma among the conditions Dr. Brothers treats.

CMS data shows 970 Medicare services from Dr. Brothers across 10 procedure codes in 2024, for 273 Medicare patients. Medicare paid $54,981 for them.

CMS counts 273 Medicare patients who saw Dr. Brothers in 2024. The largest group is 65 to 74, with 120 patients. 75% of them have high blood pressure, and 60% have high cholesterol. 42% are also on Medicaid. Their average risk score is 2.61, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Brothers' median patient age at 66, with 48% women.

In 2024, Dr. Brothers wrote 834 Medicare Part D claims for 136 patients. 68% of them were for generic drugs. CMS names the drug for 623 of them, across 26 drugs with 11 or more claims each, at $3,072,591 in total drug cost. In 2023, CMS named 430 claims across 19 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Brothers for performance year 2024, reported as part of a group. Dr. Brothers accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Brothers as offering telehealth.

Dmand AI links 7 papers to Dr. Brothers, published from 2015 to 2023. 2023 was the busiest year, with 4. Dr. Brothers' most frequent co-authors are Won Jin Jeon, MD, Dani Ran Castillo, MD and Bowon Joung.

Dmand AI links Dr. Brothers to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Lymphoma, Large B-Cell, Diffuse and Lymphoma, B-Cell.

CMS Open Payments shows 63 general payments to Dr. Brothers from 19 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 50% of the total. Amgen Inc. paid the most, $1,872.

Dr. Brothers graduated from Loma Linda University School Of Medicine in 2012.

Dr. Brothers is in network with 16 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.